

**Alzheimer's: The Puzzle, The Partners, The Path Forward**

**October 23, 2013**

**Participant Biographies  
(In Order of Agenda)**

## **OPENING REMARKS**



**Dr. William W. Chin, M.D.**  
**Executive Vice President, Science and Regulatory Affairs**  
**PhRMA**

Dr. William W. Chin is the Executive Vice President, Science and Regulatory Affairs at PhRMA, where he leads the organization's continuing efforts in science advocacy in the drug discovery and development ecosystem.

Before joining PhRMA in July 2013, Dr. Chin was the Executive Dean for Research, Bertarelli Professor of Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). In this role, he spearheaded efforts to design and implement the vision for research at HMS, with special emphasis on interdisciplinary and translational research that crosses departmental and institutional boundaries.

Dr. Chin is a Harvard-trained endocrinologist and longstanding faculty member. His impressive career is exemplified in part by his extensive bibliography of nearly 300 papers, chapters and books, most of which were generated during his 25 years on the Harvard Medical School faculty. During his tenure as a faculty member in the Department of Medicine at Brigham and Women's Hospital, he became chief of the Genetics Division and a Howard Hughes Medical Institute investigator, advancing to professor of Medicine, and Obstetrics, Gynecology and Reproductive Biology at HMS.

As a pioneering molecular endocrinologist at HMS, Dr. Chin embraced the early use of emerging DNA technology to make important discoveries regarding the structure, function and regulation of hormone genes. His investigations often demonstrated a translational research theme, connecting basic laboratory discoveries to their physiologic relevance in animal models and humans. He has been honored with numerous awards for research, mentorship and leadership.

Prior to HMS, Dr. Chin was at Eli Lilly and Company, where he had worked for a decade, most recently as senior vice president for Discovery Research and Clinical Investigation. He received his AB (Chemistry; summa cum laude) from Columbia University and his MD from Harvard Medical School.



**Dr. Timothy J. Garnett, FRCOG, MFFP, FFPM  
Chief Medical Officer and Senior Vice President  
Development Center of Excellence  
Eli Lilly & Company**

Dr. Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice-President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director – Duloxetine SUI Team; and European Clinical Research Physician for EVISTA.

Prior to joining Lilly, Dr. Garnett had acquired 7 years of experience, holding a variety of positions in the pharmaceutical industry in Europe with Organon Laboratories.

He qualified in Medicine at St. George's Hospital in London. He practiced Obstetrics and Gynecology for eight years prior to joining the pharmaceutical industry and conducted clinical research into menopause, pre-menstrual tension and post menopausal osteoporosis.

Dr. Garnett is a Fellow of the Royal College of Obstetricians and Gynecologists in the United Kingdom. He is also an active board member for the following: Centre for Innovation in Regulatory Science; Personalized Medicine Coalition; Indiana Health Industry Forum; and Eiteljorg Museum of American Indians and Western Art.

## **KEYNOTE ADDRESS**



**Dr. Suzanne Corkin Ph.D.**  
**Professor of Neuroscience, Emerita**  
**Department of Brain and Cognitive Sciences**  
**MIT**

Suzanne Corkin is Professor of Neuroscience, Emerita in the Department of Brain and Cognitive Sciences at MIT. She arrived at MIT in the fall of 1964, having just received her Ph.D. in Comparative and Physiological Psychology from McGill University. Her first accomplishment was establishing the Behavioral Neuroscience Laboratory at the newly opened Clinical Research Center. She joined the faculty in 1981 as an Associate Professor. Corkin's research over the last 48 years has focused on the study of patients with neurological disease, with the goal of linking specific cognitive processes, particularly memory, to discrete brain circuits. She described the long-term consequences of head injury in World War II and Korean War veterans, and the safety and efficacy of a psychosurgical procedure, cingulotomy, in patients with medication resistant psychiatric disease. Her subsequent research focused on the neural underpinnings of age-related degenerative diseases, including Alzheimer and Parkinson. She and her colleagues developed behavioral tasks that elucidated the nature and severity of individual Parkinson and Alzheimer patients' cognitive and psychiatric deficits, and innovative neuroanatomical labeling tools for visualizing brain regions that are targeted by PD or AD pathophysiology. Corkin also examined the cognitive neuroscience of healthy aging, combining behavioral testing with magnetoencephalography, fMRI, and MRI methods to characterize the neurobiological and information processing mechanisms underlying decreased cognitive control in healthy aging.

She is well known for her investigation of the famous amnesic patient, H.M., whom she met in 1962 and studied until his death in 2008. Corkin's book, *Permanent Present Tense*, was published in May 2013.

Corkin is a Fellow of the Montreal Neurological Institute, the American Psychological Association, and the American Association for the Advancement of Science. She received the David Wallace Medal from the Australian Association of Gerontology, the Smith College Medal, a MERIT Award from the National Institutes of Health, and the Baltes Distinguished Research Achievement Award from the American Psychological Association, Division on Aging. She received the Brain and Cognitive Sciences Undergraduate Advising Award in 2011.

## **PANEL I: PRE-COMPETITIVE PARTNERSHIPS (ALPHABETICALLY)**



**Dr. Paul Aisen, M.D.**  
**Director**  
**Alzheimer's Disease Cooperative Study**

Paul Aisen, M.D., has conducted therapeutic research on Alzheimer's disease for the past two decades.

After graduating from Harvard College, Dr. Aisen received his medical degree from the Columbia University College of Physicians and Surgeons in 1979 and pursued his clinical training as a Resident in the Department of Medicine at the University Hospitals of Cleveland, and in the Department of Medicine at the The Mount Sinai Hospital in New York. He completed his Fellowship in the Division of Rheumatology at the New York University Medical Center before returning to The Mount Sinai Hospital as Chief Resident in the Department of Medicine. Dr. Aisen is a diplomate of the American Board of Internal Medicine, with specialty certification in Rheumatology and Geriatric Medicine.

After 15 years on the faculty at Mount Sinai, Dr. Aisen moved to Georgetown University in 1999 as Professor in the Departments of Neurology and Medicine and became Vice Chair of the Department of Neurology in 2004. Since 2007 he has been Professor of Neurosciences at the University of California, San Diego. Dr. Aisen has collaborated extensively with the biotech and pharmaceutical industries for many years. He has led numerous multicenter trials, and has authored over 250 scientific papers. He is Director of the Alzheimer's Disease Cooperative Study, a consortium funded by the National Institute on Aging to develop assessment instruments and conduct clinical trials.



**Dr. Neil S. Buckholtz, Ph.D.**  
**Director of the Division of Neuroscience**  
**National Institute on Aging**  
**National Institutes of Health**

Neil S. Buckholtz, Ph.D., is currently Director of the Division of Neuroscience (DN) at the National Institute on Aging, National Institutes of Health (NIH), Bethesda, Maryland. The DN supports extramural research to understand the neural and behavioral processes associated with the aging brain. A major focus of DN is the support of basic, clinical, and epidemiological studies of Alzheimer's disease.

Dr. Buckholtz was Chief of the Dementias of Aging Branch of DN from 1993-2012. This involved overall programmatic responsibility for development, coordination, and implementation of basic and clinical Alzheimer's disease (AD) research. Dr. Buckholtz holds a doctorate in physiological psychology from the University of Wisconsin, Madison and was a faculty member at the Medical University of South Carolina, Department of Psychiatry, from 1970-1983, before coming to NIH.



**Dr. Howard Martin Fillit, M.D.**  
**Executive Director and Chief Science Officer**  
**Alzheimer's Drug Discovery Foundation**

Howard Fillit, MD is the founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF), a NYC-based not-for-profit organization whose mission is to rapidly accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease. He is an internationally recognized geriatrician and neuroscientist and expert in Alzheimer's disease.

Dr. Fillit has had a distinguished academic medicine career that includes clinical training in internal medicine at the Beth Israel Medical Center (NYC) and a fellowship in nephrology at the New York Hospital; Dr. Fillit was a fellow and assistant professor at The Rockefeller University in the laboratory of Professor Maclyn McCarty (who demonstrated in 1944 that DNA is the molecule that carries the genes of life, enabling the discovery of the double helix by Watson and Crick). During this period, Dr. Fillit also held positions at the Parker Institute for Geriatric Care, the SUNY-Stony Brook School of Medicine, and the Cornell University School of Medicine. In 1987, he joined the Department of Geriatrics and Adult Development at Mount Sinai, achieving the rank of tenured professor of geriatric medicine, medicine and neurobiology in 1992.

Throughout his career, Dr. Fillit has maintained a limited private practice in New York City in consultative geriatric medicine with a focus on Alzheimer's disease. He has also served as a member of the Board of Directors for several biotechnology companies, and has been a consultant to, member, or Chair of Scientific and Clinical Advisory Boards for numerous pharmaceutical, biotechnology and health care companies.

Dr. Fillit has received numerous awards, including the Alzheimer's Association's Rita Hayworth Award for Lifetime Achievement. He is a fellow of the American Geriatrics Society, the American College of Physicians, the Gerontological Society of America, and the New York Academy of Medicine. He is the author or co-author of more than 300 scientific articles, abstracts and books, including the leading international Textbook of Geriatric Medicine and Gerontology. He has given hundreds of speeches throughout the world on topics related to research and clinical care in geriatric medicine and Alzheimer's disease.

He received his bachelor of arts in neurobiology cum laude from Cornell University, and his medical degree from the SUNY-Upstate Medical University.



**Dr. Diane Stephenson, Ph.D.**  
**Executive Director**  
**Coalition Against Major Diseases**

Diane Stephenson is a neuroscientist by training with 30 years combined experience in academic neuroscience and drug discovery. She is passionate about translational science and has a long time dedication to the discovery of therapies to treat diseases of the nervous system. Diane received her undergraduate degree in Biochemistry at University of California, Santa Barbara and her Ph.D. in Medical Neurobiology from Indiana University. In her academic career, Diane focused her research on Amyotrophic Lateral Sclerosis and Alzheimer's disease while in industry she focused on drug discovery for Alzheimer's disease, stroke and Parkinson's disease. From 1981-1989, Diane was an associate research scientist at the ALS and Neuromuscular Research Foundation in San Francisco. In 1990, she joined Eli Lilly where she collaborated with pioneers of the amyloid hypothesis. At Pharmacia, Diane focused on stroke and Parkinson's disease with emphasis on primate models.

At Pfizer, she directed a lab focused on target identification, validation and prosecution of novel candidates for AD disease modification as well as defining novel candidates to treat neuropsychiatric diseases. Diane has over 55 scientific publications and six patents in the neuroscience area. Her specific areas of technical expertise include neuroimaging, neuropathology, biomarkers, neuroinflammation, synaptic biology and animal model characterization. As an ambassador for public-private partnerships, she has initiated numerous external academic collaborations including worldwide alliances. Diane joined Critical Path Institute as Director of the Coalition Against Major Diseases (CAMD) in August 2011. In her current role, Diane leads a multidisciplinary team comprised of academic experts, industry scientists, patient advocacy groups and regulatory experts collectively aimed at accelerating treatments for patients with neurodegenerative diseases.

The mission of CAMD is to accelerate the development of therapies for Alzheimer's and Parkinson's diseases by generating the best methods and tools for evaluating drug efficacy, expediting clinical trials, and streamlining review by regulatory agencies. The members of CAMD work to develop tools that can identify patients with neurodegenerative diseases at an early, asymptomatic or mildly symptomatic stage, thereby offering a greater chance for therapies to improve the quality of life for patients and families.



**David Wholley**  
**Director, The Biomarkers Consortium**  
**Foundation for the National Institutes of Health**

David Wholley manages The Biomarkers Consortium for the Foundation for the National Institute of Health. He has also served as Director of the Genetic Association Information Network (GAIN), a public-private partnership dedicated to helping discover the genetic basis of common disease, and led the development of a major public-private partnership in drug safety with the biopharmaceutical industry and FDA. Prior to joining the Foundation in 2006 Mr.

Wholley's career spanned nearly 25 years in healthcare technology management, including extensive experience in product development, sales, marketing, corporate strategy, and partnership and project development. Mr. Wholley has held senior management roles in several venture-funded technology startup companies, including head of Global Marketing and Development for First Genetic Trust, Inc. which developed software for large-scale collaborative genetic research and personalized medicine. During a 16-year career at IBM, he co-led the corporate strategy team that guided IBM's formation of its Life Sciences industry organization. Mr. Wholley holds an M.Phil. from Rutgers University and a Certificate in Business Administration from the Stern School of Business at New York University.



**John Wilbanks**  
**Chief Commons Officer**  
**Sage Bionetworks**  
**Senior Advisor to the National Coordination Office**

John Wilbanks is the Chief Commons Officer at Sage Bionetworks and a Senior Advisor to the National Coordination Office. He has worked at Harvard's Berkman Center for Internet & Society, the World Wide Web Consortium, the US House of

Representatives, and Creative Commons. John is a past affiliate of MIT's Project on Mathematics and Computation and also started a bioinformatics company called Incellico, which is now part of Selventa. He sits on the Advisory Boards for Boundless Learning, Genomic Arts, Curious, GenoSpace, Patients Like Me, and Genomera. He also serves as a Senior Fellow at Faster Cures and as a Special Advisor on the Research Commons to the University of California San Francisco's Clinical Translational Science Institute. John holds a degree in Philosophy from Tulane and studied modern letters at the Sorbonne.



**Dr. Stevin Zorn, Ph.D.**  
**Executive Vice President and US Site Head**  
**Neuroscience Research and Development**  
**Lundbeck Research USA**

Stevin Zorn is Executive Vice President and US site head for Neuroscience Research at Lundbeck Research USA since 2008. He is a member of Lundbeck's Global Research Leadership Team, Development Committee, R&D Management group, R&D Executive Committee and the US Management Group. His research focus is on discovering meaningful treatments to relieve suffering from both Psychiatric and Neurological diseases and is presently heading up Lundbeck's Disease Biology Unit on Neuroinflammation to discover breakthrough therapies for psycho-neurological diseases. Dr. Zorn received a BS degree in Chemistry from Lafayette College, Easton, PA, and MS and Ph.D. degrees in Neurotoxicology and Neuropharmacology, respectively, from the University of Texas Graduate School of Biomedical Sciences, Houston, TX. Subsequent postdoctoral research studies centered on basic research of brain and intracellular neuronal signaling mechanisms at the Rockefeller University, New York, NY, in Paul Greengard's, (Nobel Laureate) laboratory of Molecular and Cellular Neuroscience.

Prior to his current position, Dr. Zorn was with Pfizer Global Research and Development for nearly 20 years. He held positions including head of General Pharmacology, Alzheimer's Disease Development Team Leader, Head of Psychotherapeutics Biology, Head of Neuroscience Therapeutics, Co-Chaired the global Neuroscience Therapeutic Area Leadership Team including accountability for R&D as well as commercialization, and was Vice President and Global Therapeutic Area Head for Central Nervous System Disorders Research at Pfizer.

Dr. Zorn has extensive drug discovery and drug development experience across a broad range of neuro and psychiatric disorders and across the whole value chain for drug discovery and development. He has co-authored over 100 scientific research communications and patents and has contributed to the advancement of a wide variety of drug candidates. Several of these candidates, including the antipsychotic drug Geodon, which Dr. Zorn played a seminal role in discovering and developing, are now in clinical use helping to improve the lives of millions of patients suffering from CNS-related illnesses around the world.

## **Lunch: Stories from the Frontlines**



**Caroline Melo (Washington, D.C.)  
Alzheimer's Association young advocate**

Caroline Melo's father, Tom, was diagnosed with younger-onset Alzheimer's disease seven years ago at age 53 (Caroline was 15) and recently moved into a skilled nursing home. Her mother, Tina, is an important Alzheimer's Association advocate focusing on Representative John Culberson in Houston.

Caroline first attended the Alzheimer's Association's annual Advocacy Forum as a junior in college. It was the Forum's Day on the Hill that motivated her to secure an internship with Senator James Inhofe of Oklahoma and fight for more Alzheimer's research funding from the inside.

Caroline graduated from The University of Texas at Austin in the spring with a degree in Communication Studies: Human Relations with Business Foundations. She moved to Washington, D.C. to participate in the Falls Church Fellows Program in addition to her internship on the Hill.



**Terry Berry (Manassas, V.A.)**  
**Alzheimer's Association Early-Stage Advisor**

Terry Berry was diagnosed with frontotemporal dementia (FTD) in 2011 at the age of 56.

Prior to her diagnosis, Terry was marketing and enrollment coordinator for Riverside Health System and previously held a position in admissions and marketing at Lexington Rehabilitation and Healthcare.

Since her diagnosis, Terry has become heavily involved in the Alzheimer's Association National Capital Area Chapter, including starting a younger-onset support group. Terry has made public remarks at an Advisory Council on Alzheimer's Research, Care and Services meeting, attended the Alzheimer's Association Advocacy Forum in Washington D.C., participated in the Alzheimer's Association Walk to End Alzheimer's® and received the 2013 Champions Award.

As a member of the national 2013 Early-Stage Advisory Group, Terry is interested in increasing participation in clinical trials and eliminating the stigma attached to an Alzheimer's diagnosis. Terry would also like to stress the importance of physician education and providing resources for individuals newly diagnosed with the disease. According to Terry, "An Alzheimer's diagnosis is not the end of the journey."

Terry currently lives in Manassas, Virginia. She has three daughters, Julie, Lynn and April, and eight grandchildren.

**PANEL II: PRE-SYMPOMATIC CLINICAL TRIALS**  
**(ALPHABETICALLY)**



**Dr. Paul Aisen, M.D.**  
**Director**  
**Alzheimer's Disease Cooperative Study**

**(See biography in Panel I)**



**Dr. Neill R. Graff-Radford, MRCP**  
**Neurologist**  
**Mayo Clinic**

Dr. Graff-Radford graduated from the University of the Witwatersrand, South Africa in 1973, obtained his MRCP (UK) (Board Certification in Internal Medicine) in 1977 and moved to the United States in 1978. He completed a Neurology Residency at the University of Colorado Health Science Center in Denver, a fellowship in Behavioral Neurology with Dr Damasio in Iowa where he stayed on the faculty for 7 years. He has been at Mayo Clinic Jacksonville for 24 years and was promoted to full Professor at the Mayo College of Medicine in 1994. He served as Chair of the Department of Neurology for 10 years until 2004. He is the Principal Investigator on Jacksonville's component of the Mayo Alzheimer's Disease Research Center. He has published over 300 papers as well as more than 240 abstracts. Present areas of research include Alzheimer's disease and other dementias.



**Dr. Nicholas Kozauer**  
**Clinical Team Leader**  
**Division of Neurology Products**  
**Food and Drug Administration**

Dr. Kozauer is currently a Clinical Team Leader in the Division of Neurology Products (DNP) at FDA where his responsibilities include overseeing reviews for a variety of indications including cognitive disorders (e.g. Alzheimer's disease), headache, traumatic brain injury, and inner ear disorders. He has also played a significant role in the writing of the recently-released draft FDA guidance addressing the conduct of trials in early-stage Alzheimer's disease.

Dr. Kozauer completed a residency in Psychiatry at Georgetown University Hospital in 2005 where he served as Chief Resident. Following his residency, he went on to complete a combined clinical and research fellowship in Geriatric Psychiatry and Neuropsychiatry at Johns Hopkins Medical Center. Dr. Kozauer joined the FDA in 2010 and continues to maintain a faculty position at The Copper Ridge Institute affiliated with the Johns Hopkins School of Medicine.



**Alice Park**  
**Staff Writer**  
**TIME**

Alice Park is a staff writer at TIME. Since 1993, she has reported on the breaking frontiers of health and medicine in articles covering issues such as AIDS, anxiety and Alzheimer's disease. Park has received two CASE media fellowships — the first in 2000 to Harvard Medical School, where she designed a program focused on the latest understanding of AIDS, and the second in 2003 to UCLA's Medical School, where she researched the growing number of clinical applications of genomic research. In addition, Park's work has been recognized with awards of excellence from the National Arthritis Foundation as well as the National Headache Foundation.



**Dr. Andrew Satlin M.D.**  
**Executive Vice President & Head of Global Clinical Development**  
**Neuroscience and General Medicine Product Creation Unit**  
**Eisai, Inc.**

Dr. Satlin is Executive Vice-President and Head of Global Clinical Development in the Neuroscience and General Medicine Product Creation Unit at Eisai, Inc. He joined Eisai in 2008 as head of Clinical Development in Neuroscience with responsibility for clinical development plans, biomarker strategies, and operational excellence of all global drug development projects. The group is working on innovative amyloid-based approaches to Alzheimer's disease, an

AMPA antagonist for epilepsy, an orexin antagonist for insomnia, a cardiovascular outcome trial with a novel treatment for obesity, and a novel drug for thrombocytopenia. Dr. Satlin has fostered the creation of a new clinical scale for patients with Mild Cognitive Impairment and promoted the use of a novel, Bayesian adaptive design to improve success and mitigate the risks of Phase 2 studies for AD projects for disease modification and other indications.

Dr. Satlin is a graduate of Yale University and Harvard Medical School and trained in psychiatry and geriatric psychiatry at McLean Hospital in Massachusetts. As Director of Geriatric Psychiatry at McLean, he conducted NIA-sponsored research on behavioral disorders associated with dementia and established an outpatient dementia clinic, where he conducted several industry-sponsored clinical trials. Dr. Satlin then joined Novartis, where he had responsibility for the development of NCE's in Alzheimer's disease (AD), depression, and social anxiety disorder. He then led the development of a first-in-class drug for hypertension and its associated cardiovascular morbidity and mortality, led a company-wide Protocol Review Committee, and was Global Head of Regulatory for Neuroscience.



**Dr. Heather M. Snyder, Ph.D.**  
**Director, Medical and Scientific Relations**  
**Alzheimer's Association**

Dr. Snyder is the Director, Medical and Scientific Relations, at the Alzheimer's Association. She oversees the Association's International Research Grant Program, the mechanism through which the Association funds research applications. In addition to ensuring the smooth review of applications and distribution of awards to successful applicants, she is responsible for the dissemination of results and ongoing investigations to a wide range of audiences.

Dr. Snyder oversees the Association's participation in the Everyday Technology in Alzheimer's Care initiative, which is a joint effort with Intel that brings together technology researchers who are working to improve quality of life for people affected by Alzheimer's and their caregivers.

She also manages a collaborative project with the National Institute on Aging of the National Institutes of Health to develop a Common Alzheimer's Disease Research Ontology (CADRO) to enable the integration and comparative analysis of Alzheimer's research portfolios from public and private organizations in the U.S. and abroad.

Dr. Snyder received her Ph.D. from Loyola University Chicago Stritch School of Medicine and her B.A. in Biology and Religious Studies from The University of Virginia. Since graduating from Stritch, she completed a postdoctoral fellowship in the Neurobiology Program at Children's Memorial Research Center, affiliated with Northwestern University, in Chicago. During this time, she received a training fellowship from the National Institutes of Health, published papers related to mechanisms of neuronal toxicity in neurodegenerative diseases including Parkinson's disease and Alzheimer's disease, and presented topics related to areas of research in both national and international venues.

The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's disease. [www.alz.org](http://www.alz.org)



**Dr. Reed V. Tuckson, M.D.**  
**Managing Director**  
**Tuckson Health Connections**

A graduate of Howard University, Georgetown University School of Medicine, and the Hospital of the University of Pennsylvania's General Internal Medicine Residency and Fellowship Programs, where he was also a Robert Wood Johnson Foundation Clinical Scholar, Dr. Tuckson is currently the managing director of Tuckson Health Connections ([www.tucksonhealthconnections.com](http://www.tucksonhealthconnections.com)), a health and medical care consulting business that brings

people and ideas together to promote optimal health outcomes.

Previously, he enjoyed a long tenure as Executive Vice President and Chief of Medical Affairs for UnitedHealth Group, a Fortune 25 health and wellbeing company, which includes the nation's largest health insurer and the industry's most comprehensive health services company. Prior to that, Dr. Tuckson's career includes leadership positions as Senior Vice President for Professional Standards of the American Medical Association (AMA); President of the Charles R. Drew University of Medicine and Science in Los Angeles; Senior Vice President for Programs of the March of Dimes Birth Defects Foundation; and the Commissioner of Public Health for the District of Columbia.

Dr. Tuckson continues to be engaged in leadership positions across the continuum of health promotion and medical care delivery including basic science and its translation into clinical practice; the establishment of biotechnology enterprises; community and individual health enhancement; health information technology and data analysis; telemedicine; clinical care delivery and evaluation; and the integration of clinical medicine and public health systems.

Dr. Tuckson is an active member of the Institute of Medicine of the National Academy of Sciences, serving on, or chairing, several boards and committees. He is also active on the Advisory Committee to the Director of the National Institutes of Health; and serves on the Boards of Cell Therapeutics, Inc.; Howard University and the American Telemedicine Association among others. He has past service on cabinet level advisory committees concerned with health reform, infant mortality, children's health, violence, and radiation testing.

The author of *The Doctor in the Mirror*, a book and media presentation focused on patient empowerment to overcome everyday health issues for Americans 55 and older, Dr. Tuckson was honored to be included on the list of the "50 Most Powerful Physician Executives" in healthcare by *Modern Healthcare Magazine*.

## **ALZHEIMER'S: THE PATH TO 2025**



**George Vradenburg, J.D.  
Chairman and Co-Founder  
USAgainstAlzheimer's**

George Vradenburg is the Chairman and Co-Founder of USAgainstAlzheimer's, an education and advocacy campaign committed to mobilizing America to stop Alzheimer's, and convener of the Global CEO Initiative (CEOi).on Alzheimer's.

Through his USA2 work, George has brought together powerful voices to escalate the fight against Alzheimer's -- as co-convener of Leaders Engaged on Alzheimer's Disease (LEAD) (a network of major Alzheimer's-serving organizations from the not-for-profit, foundation, academic, corporate and government sectors) and as convener of the Global CEO Initiative Against Alzheimer's (a public-private initiative to link public, private and NGO efforts to implement the National Alzheimer's Goal to stop Alzheimer's by 2025). He has been named by HHS Secretary Kathleen Sebelius to serve on the National Alzheimer's Advisory Council to advise on the first-of-its-kind National Alzheimer's Strategic Plan. And, among other efforts, George has testified before Congress about the global Alzheimer's pandemic; has conceived and supported the Alzheimer's Study Group; and, through the Vradenburg Foundation, has supported the Alzheimer's Disease International World Alzheimer's Reports and the NIH's Global Alzheimer's Research Summit. George was appointed to the bipartisan Commission on Long-Term Care in 2013.

George and his wife Trish launched and co-chaired for 8 years the National Alzheimer's Gala, raising over \$10 million for the Alzheimer's Association. Before his retirement, George served in senior executive positions at AOL/Time Warner, Fox and CBS.

George is active in Washington's civic and philanthropic community, as Chairman of the Board of The Phillips Collection (America's first museum of modern art) and trustee of the University of the District of Columbia. George is also a member of the Council on Foreign Relations and the Economic Club of Washington.

In recognition of his community service, George received the Outstanding Community Leadership Award, the Golden Links Award from the Greater Washington Board of Trade and the Bridge Builders Award from the Partners for Livable Communities.

George received his B.A. from Oberlin College, magna cum laude, where he was elected to Phi Beta Kappa, and his J.D. from Harvard Law School, cum laude.

## **The Path Forward for Science and Policy (Alphabetically)**




**Robert Egge**  
**Vice President, Public Policy**  
**Alzheimer's Association**

Robert Egge is the Alzheimer's Association's Vice President of Public Policy. With policy experience in Alzheimer's and related healthcare issues, Mr. Egge leads the Association's Public Policy division based in Washington, DC. The division includes federal affairs, state affairs, public health and grassroots advocacy teams working in pursuit of policies to better serve those affected by Alzheimer's disease and related disorders. Chief among these priorities are increasing federal support for Alzheimer's research and treatment development, enhancing Alzheimer's care and support, and improving Alzheimer's planning, coordination and execution by federal and state agencies.

In his previous position as Executive Director of the Alzheimer's Study Group, Mr. Egge led a review of the broad range of challenges posed to the nation by the mounting Alzheimer crisis, and opportunities to address them. The Alzheimer's Study Group, a blue ribbon task force of national leaders co-chaired by former House Speaker Newt Gingrich and former Nebraska Senator Bob Kerrey, was created to develop a national strategic plan to address Alzheimer's disease. Mr. Egge worked closely with Gingrich, Kerrey and other Alzheimer's Study Group members including Justice Sandra Day O'Connor, Dr. Mark McClellan, Dr. Harold Varmus and Dr. David Satcher to shape and develop the group's national assessment, strategy and specific policy proposals.

Mr. Egge's editorials have appeared in a variety of newspapers including the *New York Times*, the *Financial Times*, and *Business Week*. He has also testified before various committees in the U.S. House and Senate on Alzheimer's policy, and has given frequent television, radio and print interviews on Alzheimer's and other aspects of health care policy.

Mr. Egge also serves as Vice President of the Alzheimer's Impact Movement (AIM). AIM is the sister organization of the Alzheimer's Association, created to more fully engage with and communicate to federal policy makers the urgency of addressing the Alzheimer's crisis. For more information about AIM, visit [www.alzimpact.org](http://www.alzimpact.org).



**Dr. Howard Martin Fillit, M.D.**  
**Executive Director and Chief Science Officer**  
**Alzheimer's Drug Discovery Foundation**

**(See biography in Panel 1)**